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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Hemorrhagic cystitis is a common complication with chemotherapeutic
alkylating agents. We investigated the possible prognostic factors of cyclophosphamide-
induced hemorrhagic cystitis in children.
Methods: Medical records of children (< 18 years old) with cyclophosphamide-related hemor-
rhagic cystitis were collected retrospectively from January 2000 to December 2010 in a tertiary
care center. We also prospectively enrolled children (< 18 years old) with cyclophosphamide
treatment.
Results: The retrospective study consisted of 23 patients whose median age was 11 years. The
median day of onset time was 1 day after cyclophosphamide usage. The hemato-oncological dis-
eases included acute leukemia (39.1%), lymphoma (13%), blastoma (13%), sarcoma (13%), aplas-
tic anemia (13%), and others (8.7%). Patients who received bone marrow transplantation (BMT)
had significantly longer duration of hemorrhagic cystitis than those who did not receive BMT
(p < 0.05). Serum uric acid, checked prior to and after the onset of hemorrhage cystitis, was
significantly lower after the development of hemorrhagic cystitis (p < 0.05). In the prospective
study, 11 children were enrolled with a median age of 5 years. The urinary nitrite/nitrate and
8-iso-prostaglandin F2a levels increased significantly after cyclophosphamide usage (p < 0.05).Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
du.tw (S.-H. Liu).
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692 C.-C. Wang et al.Table 1 Characteristic features
No. Age (y) Sex Daily CYC dose
administration
1 3 F 300 mg/m2; IV
2 3 M 60 mg/kg; IV
3 4 F 60 mg/kg; IV
4 5 M 60 mg/kg; IV
5 6 M 1000 mg/m2; I
6 6 F 440 mg/m2; IV
7 9 F 50 mg/kg; IV
8 10 F 2100 mg/m2; I
9 10 M 50 mg/kg; IV
10 10 M 60 mg/kg; IV
11 11 M 1000 mg/m2; I
12 11 M 200 mg/m2; IV
13 11 M 200 mg/m2; IV
14 11 F 60 mg/kg; IV
15 12 M 200 mg/m2; IV
16 12 M 60 mg/kg; IV
17 13 F 50 mg/kg; IV
18 14 M 60 mg/kg; IV
19 16 F 60 mg/kg; IV
20 16 F 1000 mg/m2; I
21 17 M 60 mg/kg; IV
22 17 F 60 mg/kg; IV
23 16 F 60 mg/kg; IV
BMT Z bone marrow transplantatio
death Z death within 1 year; N ZConclusion: Alteration serum uric acid level and BMT could be indicators for severe hemor-
rhagic cystitis. The elevated levels of urinary nitrite/nitrate and 8-iso-prostaglandin F2a
may indicate the essential roles played by nitric oxide syntheses and reactive oxidative
stress in cyclophosphamide-induced hemorrhagic cystitis. These findings may help clini-
cians formulate a better strategy for treating cyclophosphamide-induced hemorrhagic
cystitis.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Cyclophosphamide is a common alkylating antineoplastic
agent for chemotherapy1,2 with the common side effect of
causing hemorrhagic cystitis in children.3 Complications of
cyclophosphamide include urothelial damage with bladder
edema, ulceration, neovascularization, hemorrhage, and
necrosis. Incidence rates between 7% and 70% have been
reported in children with hemorrhagic cystitis.4,5 There are
often marked morbidities and mortalities with severe hem-
orrhagic cystitis in children. Mesna (2-mercaptoethane sulfo-
nate), high fluid intake, diuretics, and urine alkalinization
are themost common treatment strategies for the prevention
of hemorrhagic cystitis.6e8 However, cyclophosphamide-
induced hemorrhagic cystitis is still significantly noted even
after this side effect has been clinically managed.
Although previous studies suggested the potential mech-
anism of hemorrhagic cystitis in childrenwith chemotherapy,in 23 patients with hemorrhagi
;
route
Total CYC
dose (mg)
Use of
mesna
Uri
(pr
(m
900 Y 4.2
1540 Y N/4
2100 Y 4.6
2520 Y 6.1
V 1640 Y 3.5
2920 Y N/N
5040 Y 4.9
V 1650 Y 5.4
8000 Y 5.2
6800 Y 2.4
V 9500 Y 4.2
6360 Y N/1
1350 Y 7.9
4660 Y 4.1
1500 Y 6/N
3600 Y 6.9
3260 Y 7.9
5800 Y 10.
6240 Y 4.3
V 2100 Y 3.9
7200 Y 4.9
6890 Y 4.2
6100 Y 6.3
n; BUN/Cre Z blood urea nitroge
no data.the data are limited and the prognostic factors remain to be
established.9e11 Inducible NO synthase (iNOS) was originally
induced by inflammatory mediators in variable cell types,12
and hemorrhagic cystitis has been found to induce iNOS
expression in the urinary bladder of rats.13 In addition, 8-iso-
prostaglandin F2a produced by free radical-induced peroxi-
dation of arachidonic acid are widely used as a biomarker of
peroxidation and oxidative stress in adults.14 According
to previous studies, urinary 8-iso-prostaglandin F2a levels
served as the reactive oxidative stress indicator of oxidative
severity in asthma, chronic obstructive pulmonary disease,
interstitial lung disease, and renal injury.15,16 Abraham and
Isaac17 found that increased malondialdehyde could serve as
the oxidative stress parameter in the kidneys of rats after
treatment with cyclophosphamide. However, little informa-
tion is available about the severity assessment and predictor
of cyclophosphamide-induced hemorrhagic cystitis. The
implication of NOS and reactive oxidative species (ROS),c cystitis.
c acid
e/post)
g/dL)
Onset
time (d)
BMT Duration of
hemorrhagic
cystitis (d)
BUN/Cre
(mg/dL)
Outcome
/3 1  6 14.3/0.3
.5 12  6 12.9/0.6
/3 1 þ 9 14.4/0.4
/2 13 þ 30 40.4/0.4 Death
/N 1  3 4.1/0.3
1  5 7.8/0.8
/1.8 6 þ 16 10/0.4
/3.5 3  4 11.7/0.6 Late death
/1.9 1 þ 5 6.5/0.4 Late death
/2.4 1 þ 28 13.1/0.7 Late death
/2.3 1 þ 60 9.9/0.4
8.7 1  15 75.6/9.9 Death
/N 4  4 7.9/0.5
/2.6 12 þ 62 23.6/0.6
1  7 4.7/0.5
/2.6 2 þ 6 6.1/0.4 Late death
/3.9 1 þ 9 18/0.6
2/3.3 1 þ 15 17.8/0.7
5/2.4 1 þ 15 6.3/0.6 Late death
/3.4 3  12 8.4/0.4 Late death
/2.4 10 þ 31 32.4/0.9 Death
/1.7 1 þ 19 7.1/0.5
/N 1  4 N/N
n/creatinine; CYC Z cysclophosphamide; IV Z intravenous; Late
Figure 1 Cyclophosphamide-induced hemorrhagic cystitis
(HC) in children with or without bone marrow transplantation
(BMT). (A) Duration of hemorrhagic cystitis in children with and
without BMT. Levels of uric acid prior to and after hemorrhagic
cystitis induction (B) in children receiving cyclophosphamide
treatment with or (C) without BMT were detected. Data
are presented as mean  standard error of the mean [A,
n Z 10e13 (without BMTewith BMT); B, n Z 15; C, n Z 3e12
(without BMTewith BMT)]. *p < 0.05 as compared with (A) no
BMT group or (B and C) prior to hemorrhagic cystitis group.
Hemorrhagic cystitis in children 693which mediates the cyclophosphamide-induced hemorrhagic
cystitis, in the evaluation of the severity and predictor
of hemorrhagic cystitis has never been clinically studied.
This study investigated the prognostic factors of hemorrhagic
cystitis in children aged from 2 months to 18 years
with cyclophosphamide usage and further evaluated the
urinary nitrite/nitrate (NOx) and 8-iso-prostaglandin Fa
levels in oncology children who received cyclophosphamide
treatment.Materials and methods
This was a combined retrospective review and prospective
pilot study of children. The diagnosis of hemorrhagic
cystitis was identified in this tertiary referral center be-
tween 2000 and 2010. The inclusion criteria were patients
who were younger than 18 years and receiving cyclophos-
phamide with clinical hematuria and positive urine anal-
ysis. The exclusion criteria were patients who were older
than 18 years, with possible infection associated with
hemorrhagic cystitis, an onset time of more than 30 days
after receiving cyclophosphamide, and those presenting
with urinary tract infection or other congenital urinary
tract anomalies. The medical records of patients, including
age at presentation, symptoms, associated medication,
biochemical profiles, dosage of chemotherapy, onset time,
and duration of hemorrhagic cystitis and outcomes, were
reviewed. A total of 15 age-matched patients with a similar
underlying disease but without hemorrhagic cystitis after
cyclophosphamide treatment were selected from our
database from January 2000 to December 2010.
In the pilot study, 11 children undergoing cyclophos-
phamide treatment were invited to participate in this ter-
tiary referral center from January 2011 to December 2011.
Spot urine was checked prior to and after treatment, and
its analysis was performed to ascertain the diagnosis of
hemorrhagic cystitis via urine multisticks. If the spot uri-
nary analysis showed hematuria or gross hematuria, hem-
orrhagic cystitis was diagnosed. We collected urine samples
from patients prior to and after chemotherapy sessions at
varying intervals, e4e0 hours, 0e4 hours, 4e12 hours, and
12e24 hours, for a total of four fractions. Nitrite plus ni-
trate concentration nitrite/nitrate (NOx) and 8-iso-prosta-
glandin F2a levels were determined in urine with the Griess
method using automated commercial kits (R&D Systems,
Minneapolis, MN, USA) as previously described.18 Urine
was passed over a cadmium column that reduces nitrate to
nitrite. Subsequently, nitrite was combined with Griess
reagent to form a red azo dye that was measured spec-
trophotometrically at 538 nm. Urinary 8-iso-prostaglandin
F2a was measured with an enzyme immunoassay using
commercial kits (Cayman Chemicals, Ann Arbor, MI, USA)
that is read spectrophotometrically at 450 nm. Urinary
creatinine concentrations were measured using an auto-
mated colorimetric method. To avoid variance among
different lots, kits from the same lot were used for mea-
surement. The levels were standardized with urinary
creatinine. The procedures for sample handling and assay
were performed in accordance with the manufacturer’s
instructions. All assays were performed in duplicate.
Descriptive statistics were applied, and nominal variables
694 C.-C. Wang et al.were presented as mean or median with ranges as
indicated.
This study was approved by the Institutional Ethics
Committee of National Taiwan University Hospital, Taipei,
Taiwan (NTUH201008052R), and each participant provided
written consent prior to participation.
Statistical analysis
All data are expressed as mean  standard error of the
mean. Paired Student t test was used to evaluate possible
differences in clinical data. Significant differences from the
respective controls for each experimental test condition
were assessed using one-way analysis of variance, and
Bonferroni t-test with p < 0.05 was considered significant.
Results
Demographic data in children with hemorrhagic
cystitis
A total of 23 patients with cyclophosphamide treatment
and induction of hemorrhagic cystitis were included. The
incidence of hemorrhagic cystitis with cyclophosphamide
treatment in children in our hospital is 2.6 %. The charac-
teristic features of these 23 patients are summarized in
Table 1. The median age at diagnosis was 11 years (range,
3e17 years). The male/female ratio was 1.1:1. The median
amount of days of onset time was approximately 1 day after
cyclophosphamide usage. The median amount of days for
the duration of hemorrhagic cystitis was 9 days. The dis-
tribution of hemato-oncological disease in these patients
included acute leukemia (nZ 9, 39.1%), lymphoma (nZ 3,
13%), blastoma (nZ 3, 13%), sarcoma (nZ 3, 13%), aplastic
anemia (nZ 3, 13%), and other (nZ 2, 8.7%). The mean of
the total cyclophosphamide dose was approximately
4697 mg. Of the patients who received bone marrowTable 2 Level of uric acid in 15 patients with data in control g
Patient no. Study age (y) Uric acid
(pre/post) (mg/dL)
Control age (y)
1 3 4.2/3 4
2 4 4.6/3 3
3 5 6.1/2 5
4 9 4.9/1.8 8
5 10 5.4/3.5 10
6 10 5.2/1.9 14
7 10 2.4/2.4 8
8 11 4.2/2.3 14
9 11 4.1/2.6 16
10 12 6.9/2.6 13
11 13 7.9/3.9 13
12 16 4.35/2.4 16
13 16 3.9/3.4 16
14 17 4.9/2.4 15
15 17 4.2/1.7 16
CYC Z cyclophosphamide; MDS Z myelodysplastic syndrome.transplantation (BMT), the duration of hemorrhagic cystitis
was significantly longer than that of the patients who did
not receive BMT (p < 0.05; Fig. 1A). Among them, 16 pa-
tients underwent complete blood sampling with uric acid
detection prior to receiving chemotherapy and after hem-
orrhagic cystitis. One patient received oral allopurinol to
treat hyperuricemia; the others did not receive any medi-
cation to decrease the level of uric acid. Fifteen patients
underwent blood sampling with a mean level of uric acid
being 4.9 mg/dL prior to chemotherapy and the mean level
of uric acid being 2.6 mg/dL after hemorrhagic cystitis. In
the control group, age and sex were matched. In terms of
age, paired Student t test showed no significant difference
(pZ 0.39) between the study and the control groups. Total
cyclophosphamide dose in both groups also showed no sig-
nificant difference (pZ 0.29). Results of the comparison of
uric acid levels prior to and after cyclophosphamide
treatment with the control group is summarized in Table 2.
The higher uric acid level in the control group compared to
that in the study group in post-cyclophosphamide treat-
ment was noted (p < 0.05), and a similar trend was noted in
pre-cyclophosphamide treatment but without significant
difference (p Z 0.17). Comparing the levels of serum uric
acid prior to and after the induction of hemorrhagic cystitis
showed significantly lower levels of uric acid in patients
after hemorrhagic cystitis induction (p < 0.05; Fig. 1B). A
lower level of serum uric acid after chemotherapy was
correlated with patients receiving BMT (p < 0.05; Fig. 1C).
Three patients (13%) in the study group expired during the
hospital course, and six patients expired within 1 year.
Urine NO and 8-iso-prostaglandin F2a levels in
children with cyclophosphamide chemotherapy
Eleven patients whose age ranged from 4 years to 17 years
were included in the pilot study. The male/female ratio
was 1.7:1. No obvious hemorrhagic cystitis was noted
during chemotherapy. The urinary nitrite/nitrate levelsroup.
Uric acid
(pre/post) (mg/dL)
Total CYC dose (mg) Type of disease
10.1/1.9 791 Neuroblastoma
8.6/5.4 2200 Neuroblastoma
3.5/1.9 1320 Lymphoma
8.5/2.1 5280 Thalassemia
4.2/3.4 1960 Neuroblastoma
4.6/1.7 4800 Lymphoma
3.6/3.2 11,320 Leukemia
5.8/4.1 12,000 Aplastic anemia
5.5/5.8 4200 Thalassemia
4.6/3.3 3760 Leukemia
5.6/5.1 3600 Leukemia
7/6.1 7500 Leukemia
7.8/6.6 2400 Leukemia
4.6/5.4 9600 Leukemia
4.8/4.4 7200 MDS
Hemorrhagic cystitis in children 695were significantly increased at the fractions of 0e4 hours
and 4e12 hours after cyclophosphamide usage (p < 0.05)
and then gradually decreased at 12e24 hours (Fig. 2A).
The levels of 8-iso-prostaglandin F2a at the fractions of
4e12 hours and 12e24 hours were elevated significantly
(Fig. 2B).
Discussion
Our study showed that: (1) the level of urinary NOx
increased after cyclophosphamide treatment, which is
compatible with a previous animal study;19 (2) oxidative
stress, as indicated by 8-iso-prostaglandin F2a, was
increased after cyclophosphamide treatment; and (3) uric
acid and BMT seem to play important roles in
cyclophosphamide-induced hemorrhagic cystitis. Hemor-
rhagic cystitis poses a significant issue for children under-
going chemotherapy. Previous studies have shown that a
high incidence of hemorrhagic cystitis appears in childrenFigure 2 Urinary levels of (A) NOx (nitrite/nitrate) and (B) 8-
iso-prostaglandin F2a in children receiving cyclophosphamide
treatment. Urine samples were collected from children prior to
(e4e0 hours) and after (0e4 hours, 4e12 hours, and 12e24
hours) cyclophosphamide treatment. Data are presented as
mean  standard error of the mean (n Z 11). *p < 0.05 as
compared with the e4e0 hours group. **p < 0.05 as compared
with the 0e4 hour group.receiving conditioning chemotherapy during BMT.20,21 In
their report, Dr Lin and his colleagues22 noted that the
condition of one of the six children with acute myelogenous
leukemia was complicated with hemorrhagic cystitis after
BMT. Although the current studies showed that the common
complication after hematopoietic stem cell transplantation
in Taiwan included graft-versus-host disease, viral hepati-
tis, tuberculosis, cytomegalovirus infection, or pulmonary
dysfunction,23e25 acute kidney injury was also an important
outcome predictor.26 However, only a few studies have
discussed hemorrhagic cystitis in Taiwanese children. In the
present study, we reviewed hemorrhagic cystitis in children
over the past 10 years and found that BMT may be a po-
tential risk factor for hemorrhagic cystitis. However, the
actual role of BMT has yet to be fully elucidated; its positive
results could have been caused by accumulation dosage or
combined medical interaction.27 We also found that uric
acid may have been beneficial to these children, a finding
similar to that found in a previous study examining patients
with multiple sclerosis.28 Our clinical review showed that
the levels of serum uric acid decreased after an episode of
hemorrhagic cystitis in children receiving cyclophospha-
mide. Lower levels of uric acid after hemorrhagic cystitis
were associated with children receiving BMT. These findings
prompted us to reevaluate the optimal level of uric acid in
children undergoing chemotherapy. Although a high level of
uric acid is usually connected to the disease gout and may
compromise health, there are studies that report the
antioxidant properties of uric acid.29,30 Shimada et al31 also
found a direct and an indirect role of uric acid in acute
kidney injuries.
Cyclophosphamide has been well known as a chemo-
therapeutic agent since 1957. Hemorrhagic cystitis
was later reported to be a significant complication in pa-
tients treated with cyclophosphamide.32 The mechanism
of cyclophosphamide-induced hemorrhagic cystitis was
widely investigated, but it seems to be multifactorial and
not related to the dosage of cyclophosphamide adminis-
tered.27,33 There is evidence to prove the role of NO in
the pathogenesis of cyclophosphamide-induced hemor-
rhagic cystitis.5,19,34 There are several animal models
for cyclophosphamide-related hemorrhagic cystitis, which
include the intraperitoneal injection of cyclophosphamide
in rats or mice,13 directly injecting acrolein into the
bladder by direct incision,4,35 or modified instilling
acrolein into the bladder by a small urethral tube.19
Significant induction of iNOS expression in bladders dur-
ing cyclophosphamide-induced hemorrhagic cystitis was
also observed.3e5,32 In this study, we examined NOx (ni-
trate/nitrite) in the urinary bladder that indicated iNOS
production. The results showed the increase of level at the
fraction of 0e4 hours and decrease at the fraction of
12e12 hours, which is compatible with the results of
previous animal study.19 It also indicated the important
role of iNOS production in children undergoing cyclophos-
phamide treatment.
However, there are several proposed hypotheses for
cyclophosphamide-related hemorrhagic cystitis. It has been
shown that antioxidant glutathione prevents acrolein-
induced hemorrhagic cystitis in mice.4,34 The increase in
levels of ROS and NO has also been found during
cyclophosphamide-induced hemorrhagic cystitis.34 The
696 C.-C. Wang et al.overproduction of NO and ROS may lead to the formation of
peroxynitrite, triggering damage of cellular macromole-
cules.34,36 In our study, the biomarker of oxidative stress,
8-iso-prostaglandin F2a, was also significantly elevated
after children underwent cyclophosphamide treatment.
Mediators composed of interleukins (IL-6, IL-1b) or tumor
necrosis factor-a were studied as factors that participate in
the pathogenesis of cyclophosphamide-induced hemor-
rhagic cystitis.19,37 Urinary bladder inflammation and
overactivity were proven to be related to nuclear factor-kB
activation in a cyclophosphamide-induced hemorrhagic
cystitis rat model.38 The clinical observation of the con-
centration of uric acid and 8-isoprostane in children may
remind us of the essential role of ROS in cyclophosphamide-
induced cystitis.
In conclusion, the results of this retrospective review
study showed that the prevention of hemorrhagic cystitis
may be very important for children who are receiving BMT.
The alteration in levels of uric acid could be highly associ-
ated with hemorrhagic cystitis in children receiving cyclo-
phosphamide treatment; the level of urinary NOx
accompanying 8-iso-prostaglandin F2a increased signifi-
cantly. In addition, NOS and ROS may both play an essential
role in the development of cyclophosphamide-induced
hemorrhagic cystitis. Taken together, uric acid may
provide a protective mechanism in the case of
cyclophosphamide-triggered hemorrhagic cystitis. The
findings derived from the clinical observations in this study
may help us formulate a better strategy for treating
cyclophosphamide-induced hemorrhagic cystitis in children.Acknowledgments
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